Jacques Turgeon, BPharm, PhD
Professor of Pharmacy
Since spring 2007, Dr Jacques Turgeon has been appointed Director
of Research at the Centre hospitalier de l'Universit´┐Ż de Montr´┐Żal. From 2005-2007 he
was Vice-Rector ´┐Ż Research, Universit´┐Ż de Montr´┐Żal and from 2000-2005, he has served
as Dean of the Facult´┐Ż de pharmacie, Universit´┐Ż de Montr´┐Żal. He received his Bachelor
degree in Pharmacy in 1983 from Laval University in Quebec city followed by an MSc
degree in pharmacokinetics and a PhD degree in drug metabolism from the same
institution in 1985 and 1988, respectively. He completed post-doctoral studies from
1988 to 1990 in the department of Clinical Pharmacology, Vanderbilt University in
Click here for pdf CV
Selected Scientific Contributions
1- Turgeon J, Daleau P, Bennett PB, Wiggins
SS, Selby L and Roden DM. Block of IKs, the slow component of the delayed
rectifier K+ current, by the diuretic agent indapamide in guinea pig
ventricular myocytes. Circ Res 75:879-886, 1994.
2- Morissette P, Hreiche R and Turgeon J.
Modulatory role of verapamil treatment on the cardiac electrophysiological
effects of cisapride. Can J Physiol Pharmacol 84:1285-1290, 2006.
3- Michaud V, Vanier MC, Brouillette D, Roy
D, Verret L, Noel N, Taillon I, O'Hara G, Gossard D, Champagne M, Goodman K, Renaud
Y, Brown A, Phillips M, Ajami AM and Turgeon J. Combinaison of phenotype
assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose
requirements in heavily medicated patients. Clin Pharmacol Ther 83(5):740-748,
4- Couture L, Nash J and Turgeon J. The
ATP-Binding Cassette (ABC) transporters and their implication in drug disposition: a
special look at the heart. Pharmacol Rev 58:244-258, 2006.
5- Michaud V, Frappier M, Dumas MC and Turgeon
J. Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug
metabolism. PLoS ONE 5(12):e15666, December 2010.
Click here for PubMed listing
Research interests of Dr Turgeon have always been directed towards
the study of factors responsible for intersubject variability in drug response. More
specifically, he has developed expertise in the role of pharmacogenetics in
cardiovascular drug actions. Among his favourite topics were the study of drug-drug
interactions leading to pharmacodynamics modulation of antiarrhythmic drug action.
Dr Turgeon has integrated in his research approaches in vitro (patch-clamp
technique, in vitro metabolism and molecular biology) models as well as
designed and performed studies in healthy volunteers and patients. Dr Turgeon is
recognized internationally for his work on CYP450s and mechanisms of drug-drug
interactions. He has published more than 100 referred articles and more than 300
abstracts. Dr Turgeon has received numerous prizes for his research activities as
well as recognition by the students for his teaching skills. He is a member of
numerous societies and has been acting on the committees of several granting agencies
for several years. He has been the Director of the Quebec Cardiovascular Network of
the FRQS and the Research Director of the Quebec Heart Institute, Laval Hospital.